Loading...
XNASQDEL
Market cap3.10bUSD
Jan 08, Last price  
46.03USD
1D
-1.88%
1Q
9.67%
Jan 2017
114.89%
Name

QuidelOrtho Corp

Chart & Performance

D1W1MN
XNAS:QDEL chart
P/E
P/S
1.03
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
9.44%
Rev. gr., 5y
41.83%
Revenues
3.00b
-8.21%
78,691,00092,299,000106,015,000118,065,000128,132,000164,282,000113,339,000158,603,000155,741,000175,410,000182,615,000196,129,000191,603,000277,743,000522,285,000534,890,0001,661,668,0001,698,551,0003,266,000,0002,997,800,000
Net income
-10m
L
-6,287,000-9,259,00021,718,00013,631,00018,848,00032,883,000-11,271,0007,633,0004,993,0007,390,000-7,074,000-6,079,000-13,808,000-8,165,00074,183,00072,921,000810,287,000704,200,000548,700,000-10,100,000
CFO
280m
-68.35%
9,948,0001,222,00020,731,00027,342,00028,941,00072,843,000-10,293,00046,982,00019,633,00025,682,00035,686,00036,309,00011,815,00027,709,000136,345,000134,485,000629,763,000805,869,000885,300,000280,200,000
Earnings
May 14, 2025

Profile

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
IPO date
Feb 01, 1991
Employees
7,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122023‑002021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,997,800
 
3,266,000
 
Cost of revenue
2,513,400
2,141,500
Unusual Expense (Income)
NOPBT
484,400
1,124,500
NOPBT Margin
16.16%
34.43%
Operating Taxes
(19,000)
187,200
Tax Rate
16.65%
NOPAT
503,400
937,300
Net income
(10,100)
 
548,700
 
Dividends
Dividend yield
Proceeds from repurchase of equity
4,400
(47,900)
BB yield
-0.09%
0.97%
Debt
Debt current
166,500
207,500
Long-term debt
2,646,700
2,803,600
Deferred revenue
400
9,400
Other long-term liabilities
84,000
74,400
Net debt
2,638,500
2,645,100
Cash flow
Cash from operating activities
280,200
885,300
CAPEX
(209,300)
(140,900)
Cash from investing activities
(187,600)
(1,644,200)
Cash from financing activities
(265,800)
252,000
FCF
Balance
Cash
167,300
345,000
Long term investments
7,400
21,000
Excess cash
24,810
202,700
Stockholders' equity
2,157,900
2,130,300
Invested Capital
7,678,790
7,588,800
ROIC
6.56%
12.35%
ROCE
6.13%
14.05%
EV
Common stock shares outstanding
66,800
57,400
Price
73.70
 
85.67
 
Market cap
4,923,160
 
4,917,458
 
EV
7,561,660
7,562,558
EBITDA
941,600
1,408,100
EV/EBITDA
8.03
5.37
Interest
178,900
75,700
Interest/NOPBT
36.93%
6.73%